Organigram Holdings Inc. (TSE:OGI - Get Free Report) fell 0.4% during trading on Monday . The stock traded as low as C$2.18 and last traded at C$2.26. 174,291 shares changed hands during mid-day trading, a decline of 22% from the average session volume of 223,412 shares. The stock had previously closed at C$2.27.
Analyst Ratings Changes
Several equities research analysts have recently weighed in on the company. Canaccord Genuity Group reduced their price objective on Organigram from C$3.60 to C$3.15 and set a "speculative buy" rating for the company in a research report on Monday, December 9th. ATB Capital dropped their price objective on shares of Organigram from C$5.25 to C$3.50 in a report on Tuesday, December 17th.
View Our Latest Stock Analysis on Organigram
Organigram Trading Down 0.4 %
The company has a current ratio of 6.95, a quick ratio of 2.62 and a debt-to-equity ratio of 1.13. The stock has a market cap of C$245.37 million, a P/E ratio of -0.90, a price-to-earnings-growth ratio of 0.42 and a beta of 1.13. The business's fifty day simple moving average is C$2.21 and its 200 day simple moving average is C$2.32.
Insider Activity
In other news, Senior Officer Paolo De Luca sold 12,014 shares of the firm's stock in a transaction dated Thursday, October 24th. The shares were sold at an average price of C$2.52, for a total value of C$30,275.28. 31.32% of the stock is owned by insiders.
Organigram Company Profile
(
Get Free Report)
Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Organigram, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organigram wasn't on the list.
While Organigram currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
